Gene Therapy, In-Vivo and Insulin - Clinical Research Informer

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

pharmaphorum

AUGUST 24, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that could be worth up to $1.2 If approved, it could mount a challenge to bluebird bio’s gene therapy Zynteglo, which is already approved in Europe.

Gene Editing

Gene Editing Gene In-Vivo Genetics

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

JANUARY 14, 2024

Moreover, the exuberant development of biologics has revolutionized the treatment of a range of therapeutic conditions, which has further contributed to the exponential growth in the current demand for biologic therapies developed by biologics manufacturing companies.

Contract Manufacturing

Contract Manufacturing Protein Manufacturing Production

Clinical Research Informer

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

Biologics – The Next Step in Revolutionary Medication

Webinars

Stay Connected